By Shigeyuki Matsui, Marc Buyse, Richard Simon
An rising scientific trials paradigm for predictive drugs comprises the advance of molecular diagnostics to permit the prediction of the consequences of remedy or results of person sufferers. This publication bargains statistical advice on carrying out medical trials for predictive medication. It covers statistical themes correct to the most medical examine stages for constructing molecular diagnostics and therapeutics. The publication explains easy methods to establish molecular biomarkers utilizing DNA microarrays, validate the built biomarkers, and make sure their scientific application in randomized scientific trials. �Read more...
Read Online or Download Design and Analysis of Clinical Trials for Predictive Medicine PDF
Similar biostatistics books
A pragmatic undergraduate textbook for maths-shy biology scholars displaying how uncomplicated maths finds very important insights.
This booklet introduces the reader to the kinetic research of quite a lot of organic tactics on the molecular point. It exhibits that an analogous technique can be utilized to unravel the variety of steps for a variety of platforms together with enzyme reactions, muscle contraction, visible conception, and ligand binding.
Dieses Buch ist als EinfUhrung in die Theoretische Okologie gedacht. Den Begriff "okologisches Modell" habe ich im Titel absichtlich vermieden, denn hierzu ziihlen ganz verschiedene Methoden der mathematischen Beschreibung von okologischen V orgiingen. Ziel einer Theorie ist es, ein Verstandnis fUr die Vor gange und funktionellen Zusammenhange eines Fachgebietes zu erlangen.
Additional resources for Design and Analysis of Clinical Trials for Predictive Medicine
36. Huang Y, Pepe MS, and Feng Z. Evaluating the predictiveness of a continuous marker. Biometrics, 2007; 63:1181–1188. 37. Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. , 2003. 38. Gu W and Pepe M. Measures to summarize and compare the predictive capacity of markers. The International Journal of Biostatistics, October 1, 2009; 5(1):Article27. 39. Molinaro A, Simon R, and Pfeiffer R. Prediction error estimation: A comparison of resampling methods. Bioinformatics, 2005; 21:3301–3307.
FDA website, Washington, DC, 2004. 3. Oldenhuis CN, Oosting SF, Gietema JA et al. Prognostic vs predictive value of biomarkers in oncology. European Journal of Cancer, 2008; 44:946–953. 4. Atkinson AJ, Colburn WA, DeGruttola VG et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clinical Pharmacology Therapy, 2001; 69:89–95. 5. Kleinbaum DG, Sullivan KM, and Barker ND. A Pocket Guide to Epidemiology. Springer, New York, 2007. 6. NIH consensus conference. Treatment of early-stage breast cancer.
Drug companies have set ambitious goals around the delivery of personalized medicines to the patients. These goals have created an environment in which an increased focus is being given to the incorporation of predictive biomarkers into clinical development plans. Here we present some issues arising when evaluating diagnostics (Dx) in clinical development programs. One approach to such development is to incorporate the known biomarker (single or complex) into the clinical development program from the beginning, and design appropriate proof of concept (POC) experiments evaluating drug activity in diagnostically defined patient subsets.
Design and Analysis of Clinical Trials for Predictive Medicine by Shigeyuki Matsui, Marc Buyse, Richard Simon